Cellular origin of microRNA-371a-3p in healthy males based on systematic urogenital tract tissue evaluation.
microRNA-371a-3p
semen biomarker
spermatogenesis
testicular neoplasm
urogenital tract
Journal
Andrology
ISSN: 2047-2927
Titre abrégé: Andrology
Pays: England
ID NLM: 101585129
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
17
12
2018
revised:
09
01
2019
accepted:
21
01
2019
pubmed:
21
2
2019
medline:
21
7
2020
entrez:
21
2
2019
Statut:
ppublish
Résumé
The microRNA-371a-3p (miR-371a-3p) has been reported to be an informative liquid biopsy (serum and plasma) molecular biomarker for both diagnosis and follow-up of patients with a malignant (testicular) germ cell tumor ((T)GCT). It is expressed in all histological cancer elements, with the exception of mature teratoma. However, normal testis, semen, and serum of males with a disrupted testicular integrity without a TGCT may contain miR-371a-3p levels above threshold, of which the cellular origin is unknown. Therefore, a series of relevant tissues (frozen and formalin-fixed paraffin-embedded (FFPE), when available) from the complete male urogenital tract (i.e., kidney to urethra and testis to urethra) and semen was investigated for miR-371a-3p levels using targeted quantitative RT-PCR (qRT-PCR). In total, semen of males with normospermia (n = 11) and oligospermia (n = 3) was investigated, as well as 88 samples derived from 32 different patients. The samples represented one set of tissues related to the entire male urogenital tract (11 anatomical locations), three sets for 10 locations, and four sets for six locations. All testis parenchyma (n = 17) cases showed low miR-371a-3p levels. Eight out of 14 (57%) semen samples showed detectable miR-371a-3p levels, irrespective of the amount of motile spermatozoa, but related to sperm concentration and matched Johnsen score (Spearman's rho correlation coefficient 0.849 and 0.871, p = 0.000, respectively). In all other tissues investigated, miR-371a-3p could not be detected. This study demonstrates that the miR-371a-3p in healthy adult males is solely derived from the germ cell compartment. The observation is important in the context of applying miR-371a-3p as molecular liquid biopsy biomarker for diagnosis and follow-up of patients with malignant (T)GCT. Moreover, miR-371a-3p might be an informative seminal biomarker for testicular germ cell composition.
Sections du résumé
BACKGROUND
The microRNA-371a-3p (miR-371a-3p) has been reported to be an informative liquid biopsy (serum and plasma) molecular biomarker for both diagnosis and follow-up of patients with a malignant (testicular) germ cell tumor ((T)GCT). It is expressed in all histological cancer elements, with the exception of mature teratoma. However, normal testis, semen, and serum of males with a disrupted testicular integrity without a TGCT may contain miR-371a-3p levels above threshold, of which the cellular origin is unknown.
OBJECTIVES
Therefore, a series of relevant tissues (frozen and formalin-fixed paraffin-embedded (FFPE), when available) from the complete male urogenital tract (i.e., kidney to urethra and testis to urethra) and semen was investigated for miR-371a-3p levels using targeted quantitative RT-PCR (qRT-PCR).
MATERIALS AND METHODS
In total, semen of males with normospermia (n = 11) and oligospermia (n = 3) was investigated, as well as 88 samples derived from 32 different patients. The samples represented one set of tissues related to the entire male urogenital tract (11 anatomical locations), three sets for 10 locations, and four sets for six locations.
RESULTS
All testis parenchyma (n = 17) cases showed low miR-371a-3p levels. Eight out of 14 (57%) semen samples showed detectable miR-371a-3p levels, irrespective of the amount of motile spermatozoa, but related to sperm concentration and matched Johnsen score (Spearman's rho correlation coefficient 0.849 and 0.871, p = 0.000, respectively). In all other tissues investigated, miR-371a-3p could not be detected.
DISCUSSION
This study demonstrates that the miR-371a-3p in healthy adult males is solely derived from the germ cell compartment.
CONCLUSIONS
The observation is important in the context of applying miR-371a-3p as molecular liquid biopsy biomarker for diagnosis and follow-up of patients with malignant (T)GCT. Moreover, miR-371a-3p might be an informative seminal biomarker for testicular germ cell composition.
Identifiants
pubmed: 30786164
doi: 10.1111/andr.12595
pmc: PMC6767197
doi:
Substances chimiques
MIRN371 microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
463-468Subventions
Organisme : Erasmus MC
Pays : International
Organisme : Dutch Cancer Society
ID : KWF 13-6001
Pays : International
Informations de copyright
© 2019 The Authors. Andrology published by John Wiley & Sons Ltd on behalf of American Society of Andrology and European Academy of Andrology.
Références
J Cell Mol Med. 2019 Feb;23(2):1128-1136
pubmed: 30536846
Cell. 2006 Mar 24;124(6):1169-81
pubmed: 16564011
Cell Oncol (Dordr). 2017 Aug;40(4):379-388
pubmed: 28612337
Urology. 2010 Sep;76(3):521-7
pubmed: 20472270
Nature. 2000 Feb 24;403(6772):901-6
pubmed: 10706289
Eur Urol. 2011 May;59(5):671-81
pubmed: 21296484
Br J Cancer. 2016 Jan 19;114(2):151-62
pubmed: 26671749
Nat Rev Urol. 2016 Dec;13(12):715-725
pubmed: 27754472
Andrology. 2015 Jan;3(1):78-84
pubmed: 25187505
Hum Reprod. 2012 Apr;27(4):991-7
pubmed: 22286264
Nat Genet. 2005 Jul;37(7):766-70
pubmed: 15965474
Mol Cancer. 2014 Mar 06;13:47
pubmed: 24597607
Cell. 1993 Dec 3;75(5):843-54
pubmed: 8252621
Br J Cancer. 2012 Nov 6;107(10):1754-60
pubmed: 23059743
Andrology. 2015 Jan;3(1):129-39
pubmed: 25303610
Mol Oncol. 2013 Dec;7(6):1083-92
pubmed: 24012110
Oncotarget. 2016 Jul 27;8(35):58037-58049
pubmed: 28938535
Endocr Relat Cancer. 2012 May 24;19(3):365-79
pubmed: 22420006
Am J Clin Pathol. 2011 Jan;135(1):119-25
pubmed: 21173133
Cancer Res. 2010 Apr 1;70(7):2911-23
pubmed: 20332240
Philos Trans R Soc Lond B Biol Sci. 2018 Jun 5;373(1748):
pubmed: 29685967
Cell. 2003 Jun 13;113(6):673-6
pubmed: 12809598
Science. 2005 Sep 2;309(5740):1519-24
pubmed: 16141061
J Cancer Res Clin Oncol. 2017 Nov;143(11):2383-2392
pubmed: 28819887
Hum Reprod. 2006 Jun;21(6):1551-4
pubmed: 16473930
Eur Urol. 2017 Feb;71(2):213-220
pubmed: 27495845
Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9
pubmed: 12434020
Virchows Arch. 2012 Dec;461(6):663-8
pubmed: 23064661
Int J Androl. 2007 Aug;30(4):304-14; discussion 314-5
pubmed: 17573854
Urol Int. 2016;97(1):76-83
pubmed: 26989896
Hormones. 1970;1(1):2-25
pubmed: 5527187
J Urol. 2015 Jan;193(1):331-7
pubmed: 25046619
J Pathol. 2007 Nov;213(3):319-28
pubmed: 17893849
Nat Rev Dis Primers. 2018 Oct 5;4(1):29
pubmed: 30291251
J Urol. 2018 Jul;200(1):126-135
pubmed: 29474847
Urol Int. 2018;100(4):470-475
pubmed: 29698973
Anticancer Res. 2015 Jan;35(1):117-21
pubmed: 25550541
Endocrine. 2017 Sep;57(3):518-527
pubmed: 27796811